Last updated: October 19, 2026
Aztreonam is a mature, largely generic intravenous and intramuscular monobactam antibiotic with limited branded revenue and a strategically important role in treating serious aerobic Gram-negative infections, particularly when beta-lactam allergy restricts alternatives. Its base product has little remaining exclusivity value. Commercial upside is concentrated in hospital supply reliability, antimicrobial-resistance demand and newer combinations such as aztreonam-avibactam, rather than in standalone aztreonam pricing.
What is aztreonam and where is it used?
Aztreonam is a monocyclic beta-lactam antibiotic active primarily against aerobic Gram-negative bacteria. It does not provide clinically meaningful coverage against most Gram-positive organisms or anaerobes. The drug is administered parenterally as aztreonam for injection and, in some markets, as inhaled aztreonam lysine for cystic fibrosis-associated pulmonary infections.
| Attribute |
Aztreonam |
| Drug class |
Monobactam beta-lactam |
| Primary route |
Intravenous or intramuscular injection |
| Main organisms |
Aerobic Gram-negative bacteria |
| Key clinical niche |
Serious Gram-negative infection in selected beta-lactam-allergic patients |
| Major branded product |
Azactam |
| Generic status |
Broadly generic in the United States and other major markets |
| Pediatric use |
Established labeling, subject to indication and dosing |
| Patent position |
Foundational composition and product patents expired |
| Commercial market |
Hospital injectable and specialty infectious-disease procurement |
| Main growth driver |
Resistant Gram-negative infections and combination therapy |
Aztreonam has low systemic commercial differentiation as a standalone product. Hospitals generally purchase it through group purchasing organizations, wholesalers and government tenders. Contract terms, availability and shortage management can be more important than brand positioning.
When did aztreonam lose exclusivity?
Aztreonam lost meaningful small-molecule exclusivity decades ago. The original innovator period and associated regulatory protections have expired, allowing multiple generic suppliers to market injectable aztreonam. The product therefore has no conventional new-drug exclusivity narrative comparable with recently launched antibiotics.
The commercial consequence is substantial:
- Generic manufacturers compete largely on price, manufacturing capacity and supply reliability.
- The branded product has limited ability to sustain a premium.
- Hospital buyers can substitute among approved suppliers when supply is available.
- Revenue is exposed to procurement concentration and periodic shortages.
- Any durable pricing power depends on formulation, manufacturing complexity or combination-product differentiation.
Aztreonam’s market maturity does not eliminate its strategic value. Injectable anti-infectives can remain commercially relevant when few suppliers manufacture them or when a product is used as a specialized alternative during resistance or allergy-related treatment decisions.
What patents protect aztreonam?
The original aztreonam patent estate protected the monobactam structure, related intermediates, manufacturing processes and pharmaceutical compositions. Those foundational rights are no longer a meaningful barrier to generic entry.
The current patent analysis separates three categories:
| Patent category |
Commercial relevance |
| Original aztreonam composition patents |
Expired |
| Legacy process and formulation patents |
Largely expired or commercially immaterial |
| New aztreonam-avibactam combination patents |
Potentially relevant to combination products |
| Inhaled aztreonam delivery patents |
Product- and jurisdiction-specific |
| Manufacturing know-how |
Still relevant where production is technically difficult |
A generic company can generally pursue aztreonam injection through the abbreviated new drug application pathway under Section 505(j) of the Federal Food, Drug, and Cosmetic Act. The regulatory burden is materially lower than for a new molecular entity, although sterile injectable manufacturing, process validation and drug-shortage compliance remain important barriers.
What is the FDA regulatory status of aztreonam?
The FDA approved Azactam in 1986. The product is available as a sterile powder for injection that is reconstituted for intravenous or intramuscular administration. FDA-approved labeling covers selected infections caused by susceptible Gram-negative organisms, including lower respiratory tract, urinary tract, intra-abdominal, gynecologic, skin and skin-structure infections, and septicemia, depending on the labeled product and indication.
The FDA regulatory position is defined by three factors:
- The product is an established small-molecule antibiotic.
- Generic injectable versions are available.
- Clinical use is constrained by the narrow organism spectrum and the need for susceptibility-guided therapy.
Aztreonam is often considered in patients with serious immediate hypersensitivity to penicillins or cephalosporins because cross-reactivity is limited, although clinical decisions depend on the specific beta-lactam side chain, allergy history and institutional protocols.
The inhaled form, aztreonam lysine, is associated with cystic fibrosis treatment and has a separate commercial and regulatory profile. It should not be treated as interchangeable with injectable aztreonam when assessing market size, pricing or patent risk.
What is the Orange Book status of aztreonam?
Aztreonam injection is an established Orange Book product with generic competition. The Orange Book identifies approved reference-listed products and corresponding abbreviated applications, but it does not convert a mature injectable antibiotic into a protected market.
The practical Orange Book conclusions are:
- The original reference product does not hold meaningful market exclusivity.
- Generic aztreonam injection approvals support substitution and tender competition.
- Any active patent listing must be assessed at the specific dosage-form and product level.
- Combination products such as aztreonam-avibactam require a separate Orange Book and patent analysis.
A current Orange Book review is essential for transaction diligence because listings, applicants and patent certifications can change. The commercial conclusion remains stable: standalone aztreonam has no apparent foundational patent barrier comparable with a recently approved antibiotic. (U.S. Food and Drug Administration, 2024a)
How many patents cover aztreonam and its formulations?
The commercially important question is not the historical number of aztreonam patents but whether enforceable rights can block generic supply. For standalone aztreonam injection, the answer is generally no because the original composition and product rights expired long ago.
Formulation and delivery protection can still matter in narrower segments:
Injectable aztreonam
Injectable aztreonam is a conventional sterile powder formulation. Process controls, impurity limits, container closure systems and sterile manufacturing know-how may affect entry economics, but they do not necessarily create a listed patent barrier.
Inhaled aztreonam lysine
Aztreonam lysine for inhalation has a distinct formulation, device and delivery profile. Patents may cover the lysine form, aerosol composition, nebulizer performance, dosing schedule or delivery system. These rights can be more commercially relevant than the expired patents for injectable aztreonam.
Aztreonam-avibactam
The combination pairs aztreonam with avibactam, a beta-lactamase inhibitor. Its value comes from restoring aztreonam activity against selected metallo-beta-lactamase-producing and other resistant Gram-negative organisms. Patents may cover the combination, ratios, dosing regimens, crystalline forms, manufacturing processes and treatment methods.
What generic entry risks exist for aztreonam?
Generic entry risk is already realized for the base product. The key commercial risk is not future patent expiration but continued price erosion and supplier substitution.
Generic competition
Multiple approved or historically approved suppliers can compete for hospital contracts. Injectable antibiotics often have low unit prices but can experience sharp price increases when one or more manufacturers exit, encounter quality problems or face shortages.
Sterile manufacturing
The main entry barrier is operational. A supplier must maintain validated sterile capacity, reliable active pharmaceutical ingredient procurement and FDA-compliant quality systems. Manufacturing failures can remove supply even when patents do not restrict entry.
Hospital procurement
Large purchasers negotiate aggressively. A manufacturer without a cost or supply advantage may struggle to gain share despite regulatory approval.
Shortage-driven pricing
Aztreonam can benefit temporarily from constrained supply, but shortage-driven revenue is unstable. Buyers may switch rapidly to alternate suppliers or substitute antibiotics when clinically appropriate.
Which companies compete in the aztreonam market?
The market includes the branded reference product, generic injectable manufacturers, contract manufacturers and specialty pharmaceutical companies supplying hospital antibiotics. Supplier participation varies by country and over time because generic injectable portfolios are frequently rationalized.
The competitive landscape is shaped by:
- FDA-approved injectable capacity
- Access to sterile fill-finish operations
- Hospital group purchasing contracts
- Wholesaler inventory
- Supply-chain reliability
- Product availability during shortages
- Ability to support antimicrobial stewardship and pharmacovigilance requirements
The commercial position of any individual supplier must be measured through current NDC activity, hospital contracts and shipment data rather than corporate branding alone. Many companies do not report aztreonam revenue separately because it is bundled into a broader generic injectable portfolio.
What is the financial trajectory for aztreonam?
Standalone aztreonam has the financial profile of a mature hospital generic, not a growth-stage branded pharmaceutical.
| Financial factor |
Expected effect |
| Expired composition patents |
Limits long-term premium pricing |
| Generic competition |
Reduces average selling price |
| Hospital demand |
Provides recurring but specialized volume |
| Resistant Gram-negative infections |
Supports clinical relevance |
| Shortages |
Can create temporary price and volume spikes |
| Sterile manufacturing constraints |
Support supplier value when capacity is scarce |
| Branded promotion |
Limited economic effect |
| New combination products |
Provide the main avenue for premium growth |
Public company filings generally do not isolate aztreonam sales. That limits the reliability of standalone revenue estimates. The economic model is more appropriately assessed through market share, contract wins, average selling price, volume, shortage periods and supplier concentration.
The long-term base-product trajectory is likely flat to declining in real terms absent supply disruption or a new indication. Unit demand may remain stable because aztreonam is clinically useful, while price declines and generic substitution constrain revenue. Margin performance will depend heavily on manufacturing efficiency and capacity utilization.
How does aztreonam-avibactam change the market outlook?
Aztreonam-avibactam is the most important potential source of value expansion around the aztreonam platform. The combination addresses a clinically significant resistance problem: avibactam inhibits several serine beta-lactamases, while aztreonam can remain active against metallo-beta-lactamases that are not inhibited by avibactam.
Clinical and commercial differentiation depends on:
- Prevalence of metallo-beta-lactamase-producing organisms
- Availability of susceptibility testing
- Hospital infectious-disease protocols
- Comparative outcomes against cefiderocol, polymyxin-based therapy and other newer agents
- Reimbursement and formulary placement
- Pricing relative to existing rescue antibiotics
The combination should be valued separately from generic aztreonam. Its patent estate, regulatory exclusivity and launch economics may support a branded product even though the underlying aztreonam molecule is old. The commercial opportunity is narrower than the broad hospital antibiotic market but potentially higher margin because treatment options for highly resistant infections are limited.
In Europe, the European Medicines Agency authorized Emblaveo, an aztreonam-avibactam product, in 2024 for specified serious infections caused by aerobic Gram-negative organisms when treatment options are limited. (European Medicines Agency, 2024) Its commercial performance will depend on national reimbursement, hospital adoption and resistance surveillance.
What patent litigation and Paragraph IV challenges affect aztreonam?
No major current patent litigation is central to the standalone injectable aztreonam market. The foundational patents expired long ago, and generic entry has already occurred.
Paragraph IV activity is more relevant to newer products:
- Generic aztreonam injection applicants generally face an expired-patent product.
- Any challenge involving inhaled aztreonam would depend on the specific reference product and active listings.
- Aztreonam-avibactam will generate the more material future patent-certification and litigation risk.
- Combination-product litigation could involve formulation, dosage, method-of-use and manufacturing patents rather than the original aztreonam molecule.
A settlement involving a listed patent would need to be evaluated against the approved indication, patent expiration date, launch date and potential authorized-generic terms. No broad standalone aztreonam settlement structure determines the current market.
How does aztreonam compare with competing antibiotics?
| Product or class |
Primary advantage |
Commercial limitation |
| Aztreonam |
Beta-lactam alternative in selected allergy cases; Gram-negative activity |
Narrow spectrum; resistance can limit activity |
| Ceftazidime-avibactam |
Broad activity against many resistant Gram-negative pathogens |
Does not reliably address metallo-beta-lactamases |
| Cefiderocol |
Activity against difficult Gram-negative organisms, including some metallo-beta-lactamase producers |
Higher cost and complex stewardship positioning |
| Meropenem-vaborbactam |
Strong option for selected carbapenemase-producing organisms |
Limited utility against metallo-beta-lactamases |
| Polymyxins |
Low-cost rescue option |
Toxicity and weaker tolerability |
| Aztreonam-avibactam |
Potentially targeted option for metallo-beta-lactamase-producing infections |
Narrow population and premium-price adoption risk |
Aztreonam’s strongest competitive attribute is its clinical niche, not broad-spectrum coverage. Its weakest attribute is the absence of meaningful standalone exclusivity.
What is the geographic market outlook?
The United States is a mature generic market with significant hospital procurement concentration. Europe has a fragmented reimbursement structure, with country-level health-technology assessment and hospital purchasing decisions. Emerging markets may have greater volume potential but lower prices, variable regulatory enforcement and inconsistent access to sterile injectable products.
Geographic value is likely to be highest where:
- Resistant Gram-negative infections are prevalent.
- Beta-lactam allergy limits standard therapy.
- Hospitals maintain infectious-disease specialist programs.
- Reimbursement supports newer combination products.
- Local sterile injectable supply is constrained.
Aztreonam-avibactam has greater international growth potential than injectable aztreonam because resistance surveillance and limited treatment options can support premium positioning.
Key Takeaways
- Aztreonam injection is a mature generic antibiotic with expired foundational patent protection.
- Standalone revenue is likely stable to declining in real terms because of generic competition and limited differentiation.
- Hospital procurement, sterile manufacturing and supply reliability are the principal commercial variables.
- The Orange Book position supports generic competition rather than durable branded exclusivity.
- Inhaled aztreonam lysine has a separate formulation, device and patent analysis.
- Aztreonam-avibactam is the main potential source of premium growth and new patent value.
- Paragraph IV and litigation risk is limited for standalone aztreonam but more relevant to newer combination products.
- Competitive pressure comes from cefiderocol, ceftazidime-avibactam, meropenem-vaborbactam and polymyxin-based regimens.
- The base product’s value is defensive and supply-driven; the combination product’s value is innovation- and resistance-driven.
FAQs
Is aztreonam still under patent?
The foundational patents covering aztreonam are expired. Current patent risk relates mainly to specific inhaled formulations, delivery systems and aztreonam-avibactam combination products.
Is aztreonam a profitable drug for generic manufacturers?
It can be profitable when sterile capacity is constrained or supply is concentrated. Normal conditions produce lower-margin hospital generic economics because buyers negotiate heavily and multiple suppliers may compete.
Does aztreonam have biosimilar competition?
No. Aztreonam is a chemically synthesized small molecule, so competition occurs through generic drug applications rather than biosimilar applications.
Can aztreonam-avibactam replace existing antibiotics for resistant infections?
It may become an important option for selected resistant Gram-negative infections, particularly when metallo-beta-lactamases are involved. Use depends on susceptibility results, local guidelines and the approved product label.
What is the main investment risk for aztreonam?
For standalone aztreonam, the main risks are price erosion, low market differentiation and supplier substitution. For aztreonam-avibactam, the principal risks are narrow patient volume, reimbursement, competing resistance therapies and the cost of clinical adoption.
References
-
European Medicines Agency. (2024). Emblaveo: aztreonam/avibactam European public assessment report. https://www.ema.europa.eu/
-
Infectious Diseases Society of America. (2024). IDSA 2024 guidance on the treatment of antimicrobial-resistant Gram-negative infections. https://www.idsociety.org/
-
U.S. Food and Drug Administration. (2022). Azactam: aztreonam injection prescribing information. https://www.accessdata.fda.gov/
-
U.S. Food and Drug Administration. (2024a). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
-
U.S. Food and Drug Administration. (2024b). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/
